Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vyvgart
Efgartigimod, sold under the brand name Vyvgart, is a human IgG1 antibody fragment that works by blocking the neonatal Fc receptor (FcRn). This blocking action reduces the recycling of IgG antibodies, leading to a decrease in overall IgG levels in the body. It is primarily used to treat generalized myasthenia gravis (gMG) in adults who have antibodies against the acetylcholine receptor (AChR). Efgartigimod is classified as a biologic and specifically as a monoclonal antibody.
Efgartigimod is used to treat generalized myasthenia gravis (gMG) in adults with AChR antibodies.
Outcome:
Reduced vaccine efficacy
Mechanism:
Immunosuppression
Outcome:
Potential hypotension
Mechanism:
Additive effects
Outcome:
Reduced absorption (theoretical)
Mechanism:
Chelation/binding
Most likely new formulation: Subcutaneous injection (2025, 70% confidence)
Based on clinical trial data and post-marketing surveillance, efgartigimod has a high likelihood of maintaining its approved status for gMG.
Monoclonal Antibody, FcRn Antagonist
Immunoglobulin G1 (IgG1) Fragment